Please use this identifier to cite or link to this item:
|Title:||Third-generation antidepressants: do they offer advantages over the SSRIs?|
|Authors:||Olver, James S;Burrows, Graham D;Norman, Trevor R|
|Affiliation:||Department of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, West Heidelberg, Victoria, Australia.|
|Citation:||Cns Drugs; 15(12): 941-54|
|Abstract:||Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements. Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents.|
|Internal ID Number:||11735614|
|Subjects:||Antidepressive Agents.adverse effects.pharmacokinetics.therapeutic use|
Clinical Trials as Topic
Depressive Disorder.drug therapy.prevention & control
Serotonin Uptake Inhibitors.adverse effects.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.